Monopoly on health: who profits from bandages for orphaned patients?

Recently, a rally of orphan patients and their families took place in Kyiv. They demanded the provision of specialized bandages for individuals with the rare condition known as epidermolysis bullosa. At first glance, the situation appears straightforward: the government should supply patients with quality care products. However, a preliminary analysis by UNN revealed that this issue is part of a larger scheme, potentially benefiting a select few and operating due to one individual.

Market analysis showed that the government exclusively purchases bandages from a single manufacturer—a Swedish company. While there are other options available on the market that are significantly cheaper, they are not being procured. Why is that? The reason may lie in the tender conditions that effectively eliminate any competition. The technical specifications outlined in the tender documents are tailored perfectly to the characteristics of one specific brand's products.

This raises doubts about the transparency of the tenders. Furthermore, it begs the question: are patients' interests being considered when the price per unit is inflated several times over?

Upon examining the process of tender documentation preparation, we found that one individual plays a key role in this process. According to our data, this person not only develops the technical specifications but is also connected to the public union "Orphan Diseases of Ukraine." This union represents the interests of patients, including those with epidermolysis bullosa, yet simultaneously advocates for the use of bandages exclusively from the Swedish manufacturer. Other producers are not even considered.

Conflict of interest or systemic corruption?

The relationship between the public union and the foreign manufacturer deserves special attention. According to our sources, the union receives funding from a company that represents the interests of this manufacturer in Ukraine. Thus, the organization that should act as an advocate for patients is, in fact, promoting a single commercial entity.

This creates a vicious cycle: patients are told that there are no alternatives, the tenders are tailored for one manufacturer, and patients are left dependent on products whose prices seem unjustified.

The main question is: why does the government allow such a monopoly to exist? If there are alternatives on the market that are equal in quality, why are they not being considered? And are patients truly receiving the best options, or have they become hostages to the financial interests of a select few?

Journalists from UNN continue their investigation. We will reach out to the Ministry of Health and other relevant authorities to request an explanation for why the tenders are conducted in this manner. We also plan to obtain comments from independent medical experts and representatives of alternative suppliers.

We are determined to see this matter through to the end to find out whose interests lie behind government procurement and whether the situation can be changed in favor of patients. Stay tuned for updates, as the truth must be heard.

For reference

Epidermolysis bullosa is a rare genetic disorder that makes the skin extremely fragile. Even minor mechanical trauma can lead to blistering, open wounds, and scarring. This condition affects not only the skin but also the nails, hair, and mucous membranes. Treatment includes special wound care, the use of protective bandages, medication therapy, and surgical intervention in severe cases. Given its significant impact on patients' quality of life, ensuring access to necessary care products is critically important.